Form 4 for TYRA Tyra Biosciences, Inc.
Accepted 2026-09-17 19:29:28 ET · period of report 2026-09-15 · accession 0001193125-26-394738 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-17 19:29 | 2026-09-15 | TYRA | Harris Todd | Pres, CEO, Dir | A - Grant | $9.13 | +864 | 1.44M | +0.1% | +$7,887 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | A | A | 864 | $9.13 | 1,438,495 | D | — | — | (F1) These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. (F2) Includes restricted stock units. |